论文部分内容阅读
本报讯在2005年10月30日- 11月3日召开的第13届欧洲肿瘤学会议上,法国Gustave-Roussy学院免疫治疗部的艾斯库迪尔教授公布了一条消息:由拜耳医药保健股份公司和 Onyx制药公司联合开发的癌症治疗新药索拉非尼(Nexavar(R))在治疗晚期肾细胞癌(RCC)方面效果显著,其最新的Ⅲ期临床试验中期分析显示, 索拉非尼组与安慰剂组相比,患者的无进展生存期延长了1倍,严重不良事件的发生率与安慰剂组相当。艾斯库迪尔教授还指出,之前的研究数据和现在的数据都表明,索拉非尼可显著阻止晚期RCC的进展。
At the 13th European Conference on Oncology held from October 30 to November 3, 2005, Professor Eskudil from the Department of Immunotherapy at the Gustave-Roussy Institute in France released a message: "By Bayer HealthCare Nexavar (R), a cancer treatment drug jointly developed by Onyx Pharmaceuticals and Co., Ltd., has been shown to be effective in the treatment of advanced renal cell carcinoma (RCC). Its latest phase III clinical trial metaphase analysis showed that sorafenib Compared with placebo, patients in group had a 1-fold progression-free survival, and the incidence of serious adverse events was comparable to placebo. Professor Eskudil also pointed out that both the previous study data and the current data show that sorafenib can significantly prevent the progression of advanced RCC.